Phase I Trial of Intravenously Administered Endotoxin (Salmonella abortus equi) in Cancer Patients

Cancer Research

Volumn 51, Issue 10, 1991, Pages 2524-2530

  Engelhardt, Rupert ^a,c   Mackensen, Andreas ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; ENDOTOXIN; IBUPROFEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; ENDOTOXINS; FEMALE; HUMAN; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGE; NEOPLASMS; PLATELET COUNT; SALMONELLA; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0025856680     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 705: 487-511, 1893.
2. Coley, W. B. The treatment of inoperable malignant tumors with the toxins of eryisipelas and the Bacillus prodigiosas. Am. J. Med. Sci. 108: 50-68. 1894
3. Shear. M. J., Turner. F. C., and Perrault. A. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratili marcescens (Bacillus prodigiosas) culture filtrate. J. Nati. Cancer Inst. 4: 81-97, 1943.
4. Carlswell. E. A., Old. L. J., Kassel. R. L., Green. S., Fiore. N., and Williamson. B. An cndotoxin induced serum factor that causes necrosis of tumors. Proc. Nati. Acad. Sci. USA. 72: 3666-3670. 1975.
5. Blick. M., Sherwin. S. A., Rosenblum. M., and Guttermann J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res., 47: 2986-2989. 1987.
6. Sherman. M. L., Spriggs. D. R., Arthur. K. A., Imamura. K., Frei, E., and Kufe, D. W. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on Ipiiml etabolism. J. Clin. Oncol. 6: 344-350. 1988.
7. Feinberg. B., Kur/rock. R., Talpa?. M., Blick. M., Saks. S., and Guttermann. J. U. A Phase l trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. 6: 1328-1334. 1988.
8. Jakubowski. A. A., Casper. E. S., Gabrilove, J. L., Templeton. M., Shervin. S. A., and Oettgen. H. F. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J. Clin. Oncol. 7: 298-303. 1989.
9. Schaadt. M., Pfrcundschuh. M., Lorscheidt. G., Peter. K. M., Steinmetz. T., and Diehl. V. Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. J. Biol. Response Modif., 9: 247-250, 1990.
10. Mitchie. H. R., Manogue. K. R., Spriggs. D. R., Revhang. A., OTJwyer, S., Dinarello. C., Cerami. A., Wolff. S. M., and Wilmore. D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 118: 1481-1486. 1988.
11. Engelhard. R., Mackensen. A., Galanos. C., and Andreesen. R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J. Biol. Response Modif. 9: 480-491. 1990.
12. V'oiska. G. J., Barr. C., and Gilbertson. D. Phase-l-study of intravenous modified lipid A. Cancer Immunol. Immunother. 18: 107-112. 1984.
13. Moore. M. A. S., Gabrilove. J. L., and Sheridan. A. P. Therapeutic impli cations of serum factors inhibiting proliferation and inducing differentiation of myeloid leukemic cells. Blood Cells. 9: 125-137. 1983.
14. Westphal, O., Ludcritz. O., and Bister. F. aoeberdie Extraktion von Bakterien mit Phenol-Wasser. Z. Naturforsch. 7: 148-155. 1952.
15. Galanos. C., Ladcritz. O., and Westphal. O. Preparation and properties of slandari/ed lipopolysaccharide from Salmonella abortus equi (.N'oropyrexal). Zentralbl. Bakterol.' Parasitenkd. Infektioskr. Hyg. Abt. 243:226-244.1979.
16. Galanos. C., and Luderitz. O. Electrodialysis of lipopolysaccharides and their conversion lo uniform salt forms. Eur. J. Biochem. 54: 603-610. 1975.
17. Karnowsky. D. A. Meaningful clinical classification of therapeutic response to ami cancer drugs. Clin. Pharmacol. Ther. 2: 709-712. 1961.
18. Miller, A. B., Hoogstraten. B., Staquet. M., and Winkler. A. Reporting results of cancer treatment. Cancer (Phila.). 47: 207-214, 1981.
19. Shadle. P. J., Allen. J. I. Geier. M. D.,, and Koths. K. Detection of endogeneous macrophage colony-stimulating factor (M-CSF) in human blood. Exp. Hematol. 17: 154-159. 1989.
20. Kettelhut. I. C., Fiers. W., and Goldberg. A. I., The toxic effects of tumor necrosis factor in mo and their prevention by cyclooxygenase inhibitors. Proc. Nati. Acad. Sci. USA. 84:4273-4277, 1987.
21. Aderka. D., Fisher, S., Levo. Y., Holtmann. H., Hahn. T., and Wallach. D. Cachectin/tumor-nccrosis-factor production bv cancer patients. Lancet. 2: 1190. 1985.
22. Saarinen. U. M., Koskelo. E-K., Teppo, A-M., and Sames. M. A. Tumor necrosis factor in children with malignancies. Cancer Res. 50: 592-595. 1990.
23. Bartholeyns. J., Freudenberg. M., and Galanos. C. Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor. Infect. Immun. 55: 2230-2233.1987.
24. Wolff. S. M., Rubenstein. M., Mulholland. J. H., and Ailing D. W. Com parison of hamatologieand febrile response to endotoxin in man. Blood. 26: 190-201. 1965.
25. Mechanic. R. C., Frei. E., Landy. M., and Smith, W. W. Quantitative studies of human leukocytic and febrile response to single and repeated doses of purified bacterial endotoxin. J. Clin. Invest., 41: 162-172, 1962.
26. Michie, H. R., Spriggs, D. R., Manogue, K. R., Sherman, M. L., Revhang, A., O'Dwyer, S. T., Arthur, K., Dinarello, C. A., Cerami, A., Wolff, S. M., Kufe, D. W., and Wilmore, D. W. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (St. Louis), 104:280-285 1988.
27. Elin, R. J., Wolff, S. M., McAdam, K. P. W. J., Chedia, L., Audibert, F., Bernard, C., and Oberling, F. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J. Infect. Dis., 144: 329-336, 1981.
28. Schleimer, R. P., and Rutledge, B. K. Cultured human vascular endothelial cells acquire adhesivness for neutrophils after stimulation with interleukin 1, endotoxin and tumor-promoting phorbol diesters. J. Immunol., 136: 649-654,1986.
29. Gallatin, M., St. John, T. P., Siegelmann, M., Reichert, R., Butcher E. C., and Weissmann, I. L. Lymphocyte homing receptors. Cell, 44: 673-680, 1986.
30. Pohlmann, T. H., Stanness, K. A., Beatty, P. G., Ochs, H. D., and Harlan, J. M. An endothelial cell surface factors) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-a increases neutrophil adherence by a CDw 18-dependent mechanism. J. Immunol., 136: 4548-4553, 1986.
31. Gamble, J. R., Harlan, J. M., Klebanoff, S. J., and Vadas, M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. USA, 82: 8667-8671, 1985.
32. Haskard, D., Cavender, D., Beatty, P., Springer, T. A., and Ziff, M. T lymphocyte adhesion to endothelial cells: mechanisms demonstrated by anti-LFA-1 monoclonal antibodies. J. Immunol., 757:487-511, 1986.
33. Zimmermann, G. A., McIntyre, T. M. Neutrophil adherence to human endothelium in vitro occurs by CDw 18 (Mo 1, MAC-l/LFA-l/GP 150, 95) glycoprotein-dependent and -independent mechanisms. J. Clin. Invest., 81: 531-537, 1988.
34. Wallis, W. J., Beatty, P. G., Ochs, H. D., Harlan, J. M. Human monocyte adherence to cultured vascular endothelium: monoclonal antibody-defined mechanisms. J. Immunol., 135:2323-2330,1985.
35. Yu, C. L., Haskard, D. O., Cavender, D., Ziff, M. Effects of bacterial lipopolysaccharide on the binding of lymphocytes to endothelial cell monolayers. J. Immunol., 136:569-573, 1986.